Skip to main content
    O

    Omeros Corporation (OMER)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.92
    -0.15 (-0.88%)

    Market Cap: $1.24B

    Last updated: Nov 06, 2026 at 4:39 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    +22.84%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.05 - $0.01
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.27+92.6%
    60d ago$-0.03+20.0%
    30d ago$-0.03+20.0%
    7d ago$-0.020.0%
    Current$-0.02
    Revenue Consensus
    $37M
    Range$31M - $41M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.43
    Range$1.24 - $1.62
    2 analysts
    Revenue Consensus
    $73M
    Range$49M - $97M
    3 analysts
    Last 12 of 39 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$1.43$1.24 - $1.62--2--
    Sep 26EST
    		-$-0.02$-0.05 - $0.01--2
    1
    0
    30d
    		-
    Jun 26
    Reported Aug 13
    		$0.02N/A-+107.41%Beat2
    1
    0
    30d
    		+103.8%
    Mar 26
    Reported May 13
    		$0.57$-0.39$-0.40 - $-0.38+246.15%Beat3
    1
    0
    30d
    		+187.7%
    Dec 25
    Reported Mar 31
    		$-0.55$-0.52$-0.62 - $2.24-5.04%Miss3
    1
    0
    30d
    		+0.7%
    Sep 25
    Reported Nov 13
    		$-0.32$-0.48$-0.58 - $-0.37+33.33%Beat4
    1
    3
    30d
    		+50.0%
    Jun 25
    Reported Aug 14
    		$-0.53$-0.55$-0.74 - $-0.44+3.64%Beat4
    0
    1
    30d
    		+52.7%
    Mar 25
    Reported May 15
    		$-0.65$-0.58$-0.74 - $-0.53-12.07%Miss3
    No revisions (30d)
    		+13.3%
    Dec 24
    Reported Mar 31
    		$-0.55$-0.71$-1.07 - $-0.48+22.54%Beat3
    1
    1
    30d
    		-266.7%
    Sep 24
    Reported Nov 13
    		$-0.64$-0.77$-0.77 - $-0.64+16.88%Beat2
    No revisions (30d)
    		+22.0%
    Jun 24
    Reported Aug 7
    		$-1.12$-1.01$-1.51 - $-0.94-10.89%Miss3
    0
    1
    30d
    		-60.0%
    Mar 24
    Reported Apr 1
    		$-0.75$-0.63$-0.67 - $-0.58-19.05%Miss3
    No revisions (30d)
    		-19.0%
    Dec 23
    Reported Mar 26
    		$-0.15N/A-+72.73%Beat2
    No revisions (30d)
    		-107.3%
    Sep 23
    Reported Nov 9
    		$-0.82$-0.66$-0.68 - $-0.56-24.24%Miss3
    1
    0
    30d
    		+5.7%

    Key Metrics

    Valuation
    P/E Ratio-61.22EV/EBITDA119.37x
    Price/FCF-17.76xFCF Yield-5.63%
    Profitability
    Profit Margin324.90%Operating Margin0.26%
    ROE-576.00%ROIC-171.66%
    Financial Health
    Debt/Equity-0.89xInterest CoverageN/A
    Current Ratio1.95xQuick Ratio1.94x
    Trading Statistics
    Beta2.99Avg Volume1.15M
    52-Week High$21.2452-Week Low$6.24

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.73
    SMA 20$17.59
    SMA 50$18.38
    SMA 200$13.62
    EMA 10$17.61
    EMA 20$17.75
    EMA 50$17.51
    EMA 200$14.06

    MACD

    Line: -0.18Signal: -0.17Hist: -0.01

    ADX

    ADX: 16.2+DI: 22.7-DI: 26.5

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down40.0
    PSAR$19.83

    Bollinger Bands

    Upper Band$19.73
    Lower Band$15.45
    %B Position2436%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    43.7

    Momentum Oscillators

    Stoch %K41.7
    Stoch %D54.6
    Williams %R-74.4
    ROC (10d)2.1%
    Momentum0.35
    CCI (20d)-47.1
    MFI (14d)59.7

    Volatility Measures

    ATR (14d)$0.90(5.3%)
    StdDev (20d)1.07
    Hist Vol71.7%(High)

    Volume Flow

    VWAP$16.97
    OBV136.1M
    AD Line-31.1M
    CMF (20d)-0.129

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.9x
    VWMA (20d)$17.60

    Pivot Points

    R3$18.84
    R2$18.44
    R1$17.76
    Pivot Point$17.36
    S1$16.68
    S2$16.28
    S3$15.60

    Advanced Oscillators

    TSI-4.72
    Ultimate Osc45.5
    KST-58.83

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$28.53M$9.89M$0$0$0$0$0$0$0$0N/A$0
    Cost of Revenue$798,000$587,000N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$27.73M$9.31MN/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$27.66M$26.73M$29.08M$26.39M$32.35M$34.97M$33.35M$35.41M$59.16M$39.03M$39.77M$48.15M
    R&D$13.80M$13.36M$19.45M$15.99M$22.01M$23.85M$23.32M$24.08M$45.35M$26.77M$28.89M$31.73M
    SG&A$13.86M$13.37M$9.63M$10.40M$10.35M$11.12M$10.04M$11.32M$13.81M$12.26M$10.88M$16.42M
    Operating Income$74,000$-17,421,000$-29,081,000$-26,392,000$-32,354,000$-34,969,000$-33,355,000$-35,407,000$-59,157,000$-39,034,000$-39,765,000$-48,153,000
    Interest Income$4.63M$1.48M$0$0$1.24M$1.12M$0$0$0$3.42M$3.43M$4.41M
    Interest Expense$9.48M$5.89M$0$0$2.98M$3.65M$8.55M$0$0$8.23M$2.95M$7.92M
    Income Before Tax$6.67M$51.31M$80.43M$-26,392,000$-25,889,000$-37,565,000$-41,910,000$-35,407,000$-59,157,000$-43,850,000$-39,287,000$-51,656,000
    Income Tax Expense$29,000$57,000$0$0$0$0$0$0$0$0$0$0
    Net Income$13.23M$56.06M$81.93M$-26,392,000$-25,424,000$-33,460,000$-25,067,000$-35,407,000$-59,157,000$-37,184,000$-9,068,000$-37,750,000
    EBITDA$13.15M$57.42M$-33,796,000$-26,187,000$-23,432,000$-34,272,000$-42,758,000$-33,939,000$-59,287,000$-38,522,000$-39,157,000$-47,465,000
    EBIT$11.52M$55.73M$-29,081,000$-26,392,000$-24,147,000$-35,034,000$-33,355,000$-35,407,000$-59,157,000$-39,034,000$-39,765,000$-48,153,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OMER

    News

    Omeros faces securities fraud probe after EMA rejects drug approval twice, stock drops sharply.

    Pomerantz LLP is investigating Omeros Corporation for potential securities fraud after the European Medicines Agency (EMA) twice rejected its drug narsoplimab. The rejections, in June and October...

    Pluang•11/5/26•Bearish

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

    Pomerantz LLP is investigating Omeros Corporation (NASDAQ: OMER) on behalf of investors for potential securities fraud. The investigation follows two significant drops in Omeros's stock price after negative opinions from...

    PR Newswire•11/5/26•Bearish

    Omeros Corp (3O8.MU) Seasonal returns chart

    The article provides a seasonal returns chart for Omeros Corp (3O8.MU), displaying the average monthly price return from 2016 to 2026. It shows the stock's current performance with a delayed quote from Munich...

    Yahoo Finance Australia•11/2/26•Neutral

    Omeros (OMER) Stock Dropped, So What Is Driving Attention Now?

    Omeros (OMER) has garnered attention due to a 46.82% share price return over the past 90 days, despite a recent 2.69% drop. The company is considered 33% undervalued, with a fair value pegged at $27.50...

    Simply Wall St•11/2/26•Somewhat-Bullish

    Omeros grants CEO performance-based stock option award tied to share price

    Omeros Corporation has granted its CEO, Gregory A. Demopulos, M.D., a performance-based stock option award for up to 500,000 shares. The vesting of these options is tied to the company's stock reaching specific price...

    Investing.com•10/31/26•Bullish

    OMER Valuation and Fair Value

    P/E
    -61.2x
    Forward P/E
    75.8x
    EV/EBITDA
    119.4x
    P/FCF
    -17.8x
    PEG
    0.8x
    P/B
    -23.8x
    See GNG's fair value

    OMER Profitability: Margins, ROIC and FCF

    Operating margin
    0.3%
    Net margin
    324.9%
    ROIC
    -171.7%
    ROE
    -576.0%
    FCF yield
    -5.6%

    OMER Competitors

    CompanyTicker
    InnovAge Holding CorpINNV
    Nektar TherapeuticsNKTR
    Tandem Diabetes Care IncTNDM
    Procept Biorobotics CorpPRCT
    Artivion IncAORT
    Tourmaline Bio Inc.TRML
    Mind Medicine IncMNMD
    Silence Therapeutics PLCSLN

    Sector: Healthcare

    OMER Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    2
    Hold
    1
    Sell
    0
    Strong Sell
    0

    OMER Bull Case vs Bear Case

    Bull case

    • OMER has a 324.9% net profit margin.
    • OMER beat EPS estimates in 75.0% of its last 8 reported quarters.
    • OMER grew quarterly revenue 14.9% year over year.

    OMER Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    51.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.02
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    OMER Earnings Date

    OMER reports Nov 11, 2026. The date is estimated.

    OMER Earnings Call

    The latest OMER earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    OMER ETF Holders

    GNG tracks 8 ETFs that hold OMER. The largest weights:

    1. State Street SPDR S&P Pharmaceuticals ETF (XPH), 1.85% of the fund
    2. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    3. Vanguard Health Care Index Fund ETF Shares (VHT), 0.02% of the fund
    4. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.02% of the fund
    5. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    Open the ETF Stock Exposure tool for OMER

    See insider activity

    Frequently Asked Questions About OMER

    When does OMER report earnings?

    Omeros Corporation (OMER) is expected to report earnings on Nov 11, 2026.

    Does OMER pay dividends?

    Omeros Corporation (OMER) does not currently pay a regular dividend.

    What is OMER's market cap?

    Omeros Corporation (OMER) has a market capitalization of $1.24B with a current stock price of $16.92.

    Related stocks

    Sector: Healthcare

    All stocks starting with O

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In